A Phase 3, Randomized, Double Blinded, Placebo Controlled Study of Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery.
Latest Information Update: 09 May 2022
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Aug 2011 Primary endpoint 'Target-achievement-rate' has not been met.
- 20 Jul 2011 Patient numbers amended from 60 to 20 as reported in an abstract presented at 6th IAS 2011.
- 20 Jul 2011 Status changed from active, no longer recruiting to completed as reported in an abstract presented at 6th IAS 2011.